Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.

BioDrugs · 2023 · PMC9837020 · PMID 36592323

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Based on the pooled analysis of three phase III studies (FIXTURE, ERASURE, and SCULPTURE), secukinumab treatment led to a decreasing trend in body weight at a follow-up of 52 weeks [ 69 ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.